Abstract
Purpose: Our study explored the clinical value of dual time point FDG PET imaging for differentiating lymph node metastasis from lymph node reactive hyperplasia. Methods: The study analyzed 250 lymph nodes from bladder cancer patients. All patients underwent 18F-FDG PET/CT delayed diuretic imaging. Metabolic parameters SUVmax, SUVmean, MTV, and related delay indices before and after PET delayed imaging were obtained. Relationships with outcomes were analyzed using nonparametric analysis and multivariate analysis. ROC curves and nomograms were drawn to predict lymph node metastasis. Results: Delayed PET/CT imaging helps to detect more suspicious lymph nodes. If SUVmax = 2.0 or 2.5 was taken as cut-off, delayed imaging could increase the detection rate of metastatic lymph nodes by 4.1%, and 6.9%, respectively. Reactive hyperplasia lymph nodes were more likely to show increased lymph node-localized FDG uptake than metastatic lymph nodes on delayed FDG imaging. Metastatic lymph nodes were more likely to have whole, diffuse increased FDG uptake on delayed imaging. Short lymph node diameter, SUVmean, and DIMTV were three independent predictors for differentiating metastatic lymph nodes from reactive hyperplasia. Lymph node metastasis could be better differentiated from inflammatory hyperplasia ones by the combination of these three predictors. In high-risk patients, the probability of lymph node metastasis is as high as 97.6%. Conclusions: Dual time point imaging is helpful to detect more suspicious lymph nodes. Some hyperplasic lymph nodes had certain image characteristics using delayed imaging. Short lymph node diameter, SUVmean, and DIMTV were three important parameters for predicting lymph node metastasis.
Introduction
In the management of bladder urothelial carcinoma, accurate staging of pelvic lymph nodes is paramount for determining treatment strategy and prognosis. While $^{18}$F-FDG PET/CT is a cornerstone of non-invasive staging, it faces two significant challenges: the "bright bladder" effect, where excreted tracer masks adjacent nodes, and the "specificity gap," where reactive hyperplasia (benign inflammation) mimics metastatic uptake. This study evaluates the utility of dual-time-point (DTP) imaging to overcome these hurdles.
Methodology
The researchers implemented a DTP protocol involving an initial scan at approximately 50 minutes post-injection and a delayed scan at 120 minutes. To mitigate the "bright bladder" effect, a diuretic (furosemide) and hydration protocol were used before the second scan.
Study Population and Dataset
The retrospective analysis included 153 patients and 250 lymph nodes, all with histopathological confirmation. The cohort characteristics, including the distribution of metastatic versus hyperplastic nodes, are summarized below:
The study analyzed metabolic parameters including SUVmax, SUVmean, and Metabolic Tumor Volume (MTV), alongside their respective Delay Indices (DI), which represent the percentage change between the two imaging time points.
Results
Enhanced Detection and Diagnostic Performance
The transition from standard to delayed imaging significantly improved the detection of metastatic nodes. Specifically, using SUVmax cut-offs of 2.0 and 2.5, delayed imaging (DSUVmax) increased the detection rate of metastatic lymph nodes by 4.1% and 6.9%, respectively.
Predictive Modeling
Multivariate analysis identified three independent predictors for metastasis:
- Short-axis diameter: Anatomical size remains a critical factor.
- SUVmean: The average metabolic intensity.
- DIMTV (Delay Index of MTV): The change in metabolically active volume over time.
While metastatic nodes typically showed diffuse, whole-node increases in uptake, reactive nodes often exhibited localized "spotty" patterns or shrinking metabolic volumes (DIMTV). A combined model utilizing these three factors achieved an impressive Area Under the Curve (AUC) of 0.938. In high-risk patients where all three parameters were elevated, the probability of metastasis reached 97.6%.
Discussion and Conclusion
Dual-time-point $^{18}$F-FDG PET/CT imaging, particularly when combined with diuretic protocols, offers a superior diagnostic tool for bladder cancer staging. By integrating anatomical size with dynamic metabolic changes (DIMTV), clinicians can more accurately distinguish between malignancy and reactive hyperplasia. This approach not only improves sensitivity but also provides a high-specificity model (89.5%) that could reduce unnecessary invasive procedures for patients with benign lymphadenopathy.
Summary updated